These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23047795)

  • 21. Association of Fatigue Intensification with Cognitive Impairment during Radiation Therapy for Prostate Cancer.
    Feng LR; Espina A; Saligan LN
    Oncology; 2018; 94(6):363-372. PubMed ID: 29514170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
    Choudhury A; Arthur C; Malik J; Mandall P; Taylor C; Alam N; Tran A; Livsey J; Elliott T; Davidson S; Logue JP; Wylie J
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):661-7. PubMed ID: 25027670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT).
    Joseph KJ; Alvi R; Skarsgard D; Tonita J; Pervez N; Small C; Tai P
    Radiat Oncol; 2008 Jul; 3():20. PubMed ID: 18627617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower brain-derived neurotrophic factor levels associated with worsening fatigue in prostate cancer patients during repeated stress from radiation therapy.
    Saligan LN; Lukkahatai N; Holder G; Walitt B; Machado-Vieira R
    World J Biol Psychiatry; 2016 Dec; 17(8):608-614. PubMed ID: 25815565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SLC25A23 augments mitochondrial Ca²⁺ uptake, interacts with MCU, and induces oxidative stress-mediated cell death.
    Hoffman NE; Chandramoorthy HC; Shanmughapriya S; Zhang XQ; Vallem S; Doonan PJ; Malliankaraman K; Guo S; Rajan S; Elrod JW; Koch WJ; Cheung JY; Madesh M
    Mol Biol Cell; 2014 Mar; 25(6):936-47. PubMed ID: 24430870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported functional outcome measures and treatment choice for prostate cancer.
    Tiruye T; O'Callaghan M; Moretti K; Jay A; Higgs B; Santoro K; Boyle T; Ettridge K; Beckmann K
    BMC Urol; 2022 Nov; 22(1):169. PubMed ID: 36335325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
    Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-Occurring Symptoms Contribute to Persistent Fatigue in Prostate Cancer.
    Feng LR; Fuss T; Dickinson K; Ross A; Saligan LN
    Oncology; 2019; 96(4):183-191. PubMed ID: 30625479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
    Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
    Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring Biologic Correlates of Cancer-Related Fatigue in Men With Prostate Cancer: Cell Damage Pathways and Oxidative Stress.
    Dickinson K; Case AJ; Kupzyk K; Saligan L
    Biol Res Nurs; 2020 Oct; 22(4):514-519. PubMed ID: 32515205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Predictors of Fatigue in Men With Non-Metastatic Prostate Cancer Receiving External Beam Radiation Therapy.
    Feng L; Chen MK; Lukkahatai N; Hsiao CP; Kaushal A; Sechrest L; Saligan LN
    Clin J Oncol Nurs; 2015 Dec; 19(6):744-50. PubMed ID: 26583638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study.
    Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Radiother Oncol; 2021 Feb; 155():48-55. PubMed ID: 33075390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
    Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
    Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Tyson MD; Koyama T; Lee D; Hoffman KE; Resnick MJ; Wu XC; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Paddock LE; Stroup A; Chen V; Conwill R; McCollum D; Penson DF; Barocas DA
    Eur Urol; 2018 Jul; 74(1):26-33. PubMed ID: 29501451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a population-based prospective cohort.
    Mullins BT; Basak R; Broughman JR; Chen RC
    Cancer; 2019 Oct; 125(20):3657-3665. PubMed ID: 31256432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
    Truong PT; Berthelet E; Lee JC; Petersen R; Lim JT; Gaul CA; Pai H; Blood P; Ludgate CM
    Can J Urol; 2006 Jun; 13(3):3139-46. PubMed ID: 16813705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
    Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
    Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.